Key Highlights

  • C79 shares fell A$0.229 (-3.06%) to A$7.28 on May 1, 2026, with Market Capitalisation at A$874.83 million
  • 1H FY26 Revenue reached A$43.3 million, up 49% year-on-year, with EBITDA of A$14.3 million up 152% on the prior corresponding period
  • Total contracted PhotonAssay units rose to 72 following 14 new Lease agreements in and after the half, with sample volumes approaching one million per month

 

Share Price Performance

Chrysos Corporation Ltd (ASX: C79) shares declined A$0.229, or 3.06%, to trade at A$7.28 during the May 1, 2026 session, on relatively light Volume of 68,536 shares. The company's Market Capitalisation stood at approximately A$874.83 million. The modest share price weakness, despite a 1H FY26 result released on February 18, 2026 that delivered strong growth across all key financial metrics, may reflect broader market dynamics and longer-term re-rating considerations following a period of appreciation.

Chrysos's half-year results, while announced in February, continue to shape market perception of the stock and are referenced in the context of the company's full-year guidance trajectory and deployment pipeline. With FY26 Revenue and EBITDA now tracking toward the upper end of guidance ranges, and a new A$200 million Debt Facility secured, the fundamental backdrop for Chrysos remains materially positive.

1H FY26 Financial Performance: Revenue and EBITDA Surge

Chrysos reported total Revenue of A$43.3 million for the first half of FY26, a 49% increase on the A$29.1 million recorded in 1H FY25. EBITDA reached A$14.3 million, representing a 152% increase on the A$5.7 million recorded in the prior corresponding period, and EBITDA Margin expanded from 20% to 33% — a material improvement in the operational Leverage of the PhotonAssay Business model as scale increases.

Minimum Monthly Assay Payments (MMAP) of A$31.5 million were up 22% year-on-year, scaling in line with unit deployments. Additional Assay Charges (AAC) — which represent Revenue earned when samples exceed contracted minimums — surged to A$11.7 million, up 261% on 1H FY25's A$3.3 million. AAC now accounts for 27.1% of total Revenue, compared to just 11.2% in the prior corresponding period, reflecting the strong Demand tailwind from elevated gold prices and increased market penetration of the PhotonAssay platform.

Net operating cash inflow was A$8.56 million in 1H FY26 (A$6.14 million in 1H FY25), reinforcing the Business's capacity for self-funded growth. At the end of the half, cash and undrawn Debt totalled A$72 million, a figure that has been materially bolstered by the subsequent A$200 million Debt Facility commitment.

PhotonAssay Technology and Unit Deployment

PhotonAssay is Chrysos's flagship product — a gold and multi-element analysis technology that delivers faster, safer, more accurate, and more environmentally friendly results than conventional fire assay methods. The technology is deployed via a Lease model, whereby customers pay both minimum monthly assay fees and additional charges for higher volumes.

By the end of 1H FY26, 43 PhotonAssay units were deployed across the world, with sample volumes approaching one million samples per month — a record for the company. Chrysos signed 14 new Lease agreements during and after the half, bringing total contracted units to 72. The pipeline of contracted-but-not-yet-deployed units supports an acceleration of deployments in CY26, with four units deployed in 1H FY26 and a stronger deployment cadence expected in the second half and calendar year 2026.

Notable among the new Lease agreements was the deployment of Chrysos's first 'XN' generation unit — a next-generation model featuring simplified operation and reduced cycle times that enables higher throughput capacity. The XN unit was deployed to SGS in Perth, signalling the beginning of a fleet refresh that could further improve Revenue per unit over time.

Geographic Expansion: South America and Global Laboratories

A significant strategic development during and after 1H FY26 was Chrysos's entry into the South American market. A Lease agreement with Bureau Veritas in Chile represents the company's first deployment in South America — a major gold-producing region that has previously lacked PhotonAssay exposure. This entry was supported by a foundational Partnership with Bureau Veritas, establishing a commercial platform for further regional expansion.

Chrysos now has all four major global geochemistry laboratories — ALS, SGS, Bureau Veritas, and Intertek — actively promoting PhotonAssay to their gold Mining customers. The 1H FY26 Lease agreements also included new geographies such as the Nordics (via CRS) and Kazakhstan (with ALS), both of which expand Chrysos's presence in significant gold Mining regions that had previously not experienced the technology. The growing breadth of the global deployment base reduces geographic concentration risk and supports the company's ambitions to become the standard analytical tool for gold Mining worldwide.

New A$200 Million Debt Facility

A major corporate development announced alongside the 1H FY26 results was the receipt of binding commitments for a new A$200 million Debt Facility to refinance and replace the existing Facility. The new Facility has a three-year term and is offered on improved terms across all key aspects relative to the prior arrangement. The net increase in available Debt funding of approximately A$105 million, combined with positive operating cashflow, provides Chrysos with the financial capacity to significantly accelerate its PhotonAssay unit deployment program.

This enhanced funding position is particularly important given that each new unit deployment requires upfront Capital Investment by Chrysos, and the deployment pipeline — currently representing 72 contracted units against 43 deployed — implies a substantial Capital requirement to close the gap. The new Facility removes a potential constraint on the pace of deployment.

FY26 Guidance and Outlook

Based on strong 1H FY26 results and sustained high sample volumes, Chrysos has indicated that both Revenue and EBITDA are tracking toward the upper end of their respective FY26 guidance ranges — Revenue of A$80 million to A$90 million, and EBITDA of A$20 million to A$27 million. The positive outlook for gold prices is expected to continue providing favourable conditions for strong sample volumes, as elevated gold prices incentivise increased exploration and production activity.

The appointment of Elisha Civil to the Board as an Independent Non-Executive Director in October 2025 further strengthens the governance capability of the company as it continues to grow in scale and geographic reach.

Conclusion

Chrysos Corporation's 3.06% share price decline to A$7.28 on May 1, 2026 stands in contrast to a 1H FY26 result that delivered 49% Revenue growth, 152% EBITDA growth, Margin expansion from 20% to 33%, and a record pipeline of 72 contracted PhotonAssay units. With sample volumes approaching one million per month, entry into South America, all four major global geochemistry labs promoting the technology, and a new A$200 million Debt Facility in place to accelerate deployments, Chrysos Corporation's Business fundamentals appear robustly positioned. The pace of unit deployments and the evolution of the AAC Revenue stream relative to contracted minimums will be the metrics most closely watched by investors as the year progresses.